Jump to content

Sanofi: Difference between revisions

Sanofi (view source)

Revision as of 22:55, 21 December 2024

12 bytes removed ,  21 December 2024
m
Text replacement - "The Wall Street Journal" to "The Wall Street Journal"
VisualWikitext
m (Text replacement - "The New York Times" to "The New York Times")
m (Text replacement - "The Wall Street Journal" to "The Wall Street Journal")
 
Line 77: Line 77:
In 2006, Iraqis infected with HIV sued Sanofi and Baxter over HIV-[[contaminated haemophilia blood products]] sold by Merieux in the 1980s.<ref>{{cite news |last=Zielbauer |first=Paul von |date=4 September 2006 |title=Iraqis Infected by H.I.V.-Tainted Blood Try New Tool: A Lawsuit |work=The New York Times |url=https://www.nytimes.com/2006/09/04/world/middleeast/04aids.html |access-date=27 November 2019}}</ref> In 2006, the US patents on [[clopidogrel]] (Plavix) were challenged when a Canadian generics company, [[Apotex]], filed an [[Abbreviated New Drug Application]] under the [[Hatch-Waxman Act]], received FDA approval, and started marketing a generic formulation of clopidogrel. While Sanofi-Aventis and its partner in the drug, [[Bristol Myers Squibb]] (BMS), were able to get an injunction to stop Apotex from selling it,<ref>BMS Press Release. 8 December 2006 [http://www.prnewswire.com/news-releases/preliminary-injunction-against-apotex-upheld-on-appeal-56053592.html Preliminary Injunction Against Apotex Upheld on Appeal]</ref> the case became complicated when settlement negotiations fell apart twice – the second time because of an [[oral agreement]] made by BMS CEO Peter Dolan that BMS failed to disclose to the [[Federal Trade Commission]] during the review of the settlement agreement to ensure that it did not violate [[antitrust]] law.  When Apotex disclosed the oral agreement to the FTC, the FTC launched an investigation that led to Dolan's dismissal by BMS.<ref>Aaron Smith for CNNMoney.com 26 October 2006 [https://money.cnn.com/2006/09/12/news/companies/bristol/index.htm?postversion=2006091217 Bristol CEO Dolan gets fired: Company says it heeded request of a federal monitor]</ref> Apotex finally lost on the patent litigation issues after its third appeal was decided in favor of BMS/Sanofi in November 2011; Apotex had to pay ~$442 million in damages and ~$108 million in interest for infringing the patent,<ref>Donald Zuhn for Patent Docs. 9 November 2011 [http://www.patentdocs.org/2011/11/sanofi-aventis-v-apotex-inc-fed-cir-2011.html Sanofi-Aventis v. Apotex Inc. (Fed. Cir. 2011)]</ref> which it paid in full by February 2012.<ref>Linda a. Johnson for Associated Press 8 February 2012 [https://finance.yahoo.com/news/Apotex-pays-Bristol-Sanofi-apf-2142059502.html Apotex pays Bristol, Sanofi damages over Plavix] {{webarchive|url=https://web.archive.org/web/20160305060611/http://finance.yahoo.com/news/Apotex-pays-Bristol-Sanofi-apf-2142059502.html |date=5 March 2016 }}</ref> Apotex also sued BMS and Sanofi for $3.4 billion for allegedly breaching the settlement agreement; Apotex lost a jury trial in March 2013.<ref>Carolina Bolado for Law360 14 March 2013. [http://www.law360.com/articles/423792/bristol-myers-escapes-3-4b-apotex-suit-over-plavix-deal Bristol-Myers Escapes $3.4B Apotex Suit Over Plavix Deal]</ref>
In 2006, Iraqis infected with HIV sued Sanofi and Baxter over HIV-[[contaminated haemophilia blood products]] sold by Merieux in the 1980s.<ref>{{cite news |last=Zielbauer |first=Paul von |date=4 September 2006 |title=Iraqis Infected by H.I.V.-Tainted Blood Try New Tool: A Lawsuit |work=The New York Times |url=https://www.nytimes.com/2006/09/04/world/middleeast/04aids.html |access-date=27 November 2019}}</ref> In 2006, the US patents on [[clopidogrel]] (Plavix) were challenged when a Canadian generics company, [[Apotex]], filed an [[Abbreviated New Drug Application]] under the [[Hatch-Waxman Act]], received FDA approval, and started marketing a generic formulation of clopidogrel. While Sanofi-Aventis and its partner in the drug, [[Bristol Myers Squibb]] (BMS), were able to get an injunction to stop Apotex from selling it,<ref>BMS Press Release. 8 December 2006 [http://www.prnewswire.com/news-releases/preliminary-injunction-against-apotex-upheld-on-appeal-56053592.html Preliminary Injunction Against Apotex Upheld on Appeal]</ref> the case became complicated when settlement negotiations fell apart twice – the second time because of an [[oral agreement]] made by BMS CEO Peter Dolan that BMS failed to disclose to the [[Federal Trade Commission]] during the review of the settlement agreement to ensure that it did not violate [[antitrust]] law.  When Apotex disclosed the oral agreement to the FTC, the FTC launched an investigation that led to Dolan's dismissal by BMS.<ref>Aaron Smith for CNNMoney.com 26 October 2006 [https://money.cnn.com/2006/09/12/news/companies/bristol/index.htm?postversion=2006091217 Bristol CEO Dolan gets fired: Company says it heeded request of a federal monitor]</ref> Apotex finally lost on the patent litigation issues after its third appeal was decided in favor of BMS/Sanofi in November 2011; Apotex had to pay ~$442 million in damages and ~$108 million in interest for infringing the patent,<ref>Donald Zuhn for Patent Docs. 9 November 2011 [http://www.patentdocs.org/2011/11/sanofi-aventis-v-apotex-inc-fed-cir-2011.html Sanofi-Aventis v. Apotex Inc. (Fed. Cir. 2011)]</ref> which it paid in full by February 2012.<ref>Linda a. Johnson for Associated Press 8 February 2012 [https://finance.yahoo.com/news/Apotex-pays-Bristol-Sanofi-apf-2142059502.html Apotex pays Bristol, Sanofi damages over Plavix] {{webarchive|url=https://web.archive.org/web/20160305060611/http://finance.yahoo.com/news/Apotex-pays-Bristol-Sanofi-apf-2142059502.html |date=5 March 2016 }}</ref> Apotex also sued BMS and Sanofi for $3.4 billion for allegedly breaching the settlement agreement; Apotex lost a jury trial in March 2013.<ref>Carolina Bolado for Law360 14 March 2013. [http://www.law360.com/articles/423792/bristol-myers-escapes-3-4b-apotex-suit-over-plavix-deal Bristol-Myers Escapes $3.4B Apotex Suit Over Plavix Deal]</ref>


In 2007, Sanofi-Aventis expanded on Aventis's prior relationship with [[Regeneron Pharmaceuticals]]; in the new deal Sanofi-Aventis agreed to pay Regeneron $100 million per year for five years, under which Regeneron would use its [[monoclonal antibody]] [[drug discovery|discovery]] platform to create new [[biopharmaceuticals]], to which Sanofi-Aventis gained the exclusive right to co-develop.<ref name="RegenExpand">{{cite news |last=Winslow |first=Ron |date=10 November 2009 |title=Sanofi Expands Regeneron Deal |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/SB10001424052748703808904574528224003357650 |access-date=27 November 2019}}</ref> In 2009, the companies expanded the deal to $160 million per year and extended it to 2017.<ref name=RegenExpand/><ref name="GEN2009">Genetic Engineering and Biotechnology News. 11 November 2009 [http://www.genengnews.com/gen-news-highlights/sanofi-aventis-commits-over-2-8b-to-regeneron-in-mab-discovery-alliance/68174500/ Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance]</ref>  {{As of|2009}}, the collaboration had four antibodies in clinical development and had filed an IND for a fifth. Two were against undisclosed targets, one targeted the [[interleukin-6]] [[Cell surface receptor|receptor]] as a treatment for [[rheumatoid arthritis]], another targeted [[nerve growth factor]] for the treatment of pain, and another targeted [[DLL4|delta-like ligand 4]] as a cancer treatment.<ref name=GEN2009/>
In 2007, Sanofi-Aventis expanded on Aventis's prior relationship with [[Regeneron Pharmaceuticals]]; in the new deal Sanofi-Aventis agreed to pay Regeneron $100 million per year for five years, under which Regeneron would use its [[monoclonal antibody]] [[drug discovery|discovery]] platform to create new [[biopharmaceuticals]], to which Sanofi-Aventis gained the exclusive right to co-develop.<ref name="RegenExpand">{{cite news |last=Winslow |first=Ron |date=10 November 2009 |title=Sanofi Expands Regeneron Deal |work=The Wall Street Journal |url=https://www.wsj.com/articles/SB10001424052748703808904574528224003357650 |access-date=27 November 2019}}</ref> In 2009, the companies expanded the deal to $160 million per year and extended it to 2017.<ref name=RegenExpand/><ref name="GEN2009">Genetic Engineering and Biotechnology News. 11 November 2009 [http://www.genengnews.com/gen-news-highlights/sanofi-aventis-commits-over-2-8b-to-regeneron-in-mab-discovery-alliance/68174500/ Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance]</ref>  {{As of|2009}}, the collaboration had four antibodies in clinical development and had filed an IND for a fifth. Two were against undisclosed targets, one targeted the [[interleukin-6]] [[Cell surface receptor|receptor]] as a treatment for [[rheumatoid arthritis]], another targeted [[nerve growth factor]] for the treatment of pain, and another targeted [[DLL4|delta-like ligand 4]] as a cancer treatment.<ref name=GEN2009/>


Between 2008, when [[Chris Viehbacher]] was hired as CEO, and 2010, the company spent more than $17 billion in mergers and acquisitions to strengthen its consumer healthcare and generics platforms, especially in emerging markets, in the face of looming [[patent cliff]]s and the growth of the consumer healthcare segment.<ref>FierceBiotech. [http://www.fiercebiotech.com/special-reports/sanofi-aventis-timeline-biopharma-deals Sanofi-Aventis: A timeline of biopharma deals]</ref><ref>Andy Tisman for IMS Health 2010 [http://www.imshealth.com/deployedfiles/ims/Global/Content/Solutions/Healthcare%20Measurement/Consumer%20Health%20Insights/The_Rising_Tide_Of_OTC_Europe.pdf The Rising Tide of OTC in Europe]</ref><ref name=Chattem/> In September, [[Zentiva]] was acquired for €1.8 billion, expanding the group's presence in eastern European markets.<ref>{{cite news |date=22 September 2008 |title=Sanofi-Aventis to buy Czech generic drug maker |work=The New York Times |url=https://www.nytimes.com/2008/09/22/business/worldbusiness/22iht-drug.4.16376740.html |access-date=27 November 2019}}</ref>
Between 2008, when [[Chris Viehbacher]] was hired as CEO, and 2010, the company spent more than $17 billion in mergers and acquisitions to strengthen its consumer healthcare and generics platforms, especially in emerging markets, in the face of looming [[patent cliff]]s and the growth of the consumer healthcare segment.<ref>FierceBiotech. [http://www.fiercebiotech.com/special-reports/sanofi-aventis-timeline-biopharma-deals Sanofi-Aventis: A timeline of biopharma deals]</ref><ref>Andy Tisman for IMS Health 2010 [http://www.imshealth.com/deployedfiles/ims/Global/Content/Solutions/Healthcare%20Measurement/Consumer%20Health%20Insights/The_Rising_Tide_Of_OTC_Europe.pdf The Rising Tide of OTC in Europe]</ref><ref name=Chattem/> In September, [[Zentiva]] was acquired for €1.8 billion, expanding the group's presence in eastern European markets.<ref>{{cite news |date=22 September 2008 |title=Sanofi-Aventis to buy Czech generic drug maker |work=The New York Times |url=https://www.nytimes.com/2008/09/22/business/worldbusiness/22iht-drug.4.16376740.html |access-date=27 November 2019}}</ref>


In 2009, Medley Farma, the third largest pharmaceutical company in Brazil and a leading generics company there, was acquired for about $635 million.<ref name="Law360Medley">Leigh Kamping-Carder for Law360. 20 May 2010 [http://www.law360.com/articles/169962/brazil-clears-sanofi-s-635m-medley-pharma-buy Brazil Clears Sanofi's $635M Medley Pharma Buy]</ref> Sanofi outbid [[Teva Pharmaceuticals]].<ref>Gareth Macdonald for PharmaTechnologist, 15 April 2009 [http://www.in-pharmatechnologist.com/Regulatory-Safety/Sanofi-beats-Teva-in-Medley-melee Sanofi beats Teva in Medley melee]</ref> The deal was approved by Brazil's antitrust authorities in May 2010.<ref name=Law360Medley/> Later that year, Indian vaccine manufacturer [[Shantha Biotechnics]] was acquired for $784 million.<ref>{{Cite web |title=Sanofi snaps up India's Shantha for $784M |url=http://www.fiercebiotech.com/story/sanofi-snaps-indias-shantha-784m/2009-07-27 |website=FierceBiotech|date=27 July 2009 }}</ref> In October Sanofi-Aventis announced that it would lay off about 1700 US employees (about 25% of its US workforce) because of restructuring triggered by growing generic competition and other factors, and that the company would focus its US operations on diabetes, atrial fibrillation, and oncology.<ref>{{cite news |last1=Gryta |first1=Thomas |last2=Spencer |first2=Mimosa |date=9 October 2010 |title=Sanofi Cuts Jobs, Counters Genzyme |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/SB10001424052748704657304575540024140661094 |access-date=27 November 2019}}</ref>
In 2009, Medley Farma, the third largest pharmaceutical company in Brazil and a leading generics company there, was acquired for about $635 million.<ref name="Law360Medley">Leigh Kamping-Carder for Law360. 20 May 2010 [http://www.law360.com/articles/169962/brazil-clears-sanofi-s-635m-medley-pharma-buy Brazil Clears Sanofi's $635M Medley Pharma Buy]</ref> Sanofi outbid [[Teva Pharmaceuticals]].<ref>Gareth Macdonald for PharmaTechnologist, 15 April 2009 [http://www.in-pharmatechnologist.com/Regulatory-Safety/Sanofi-beats-Teva-in-Medley-melee Sanofi beats Teva in Medley melee]</ref> The deal was approved by Brazil's antitrust authorities in May 2010.<ref name=Law360Medley/> Later that year, Indian vaccine manufacturer [[Shantha Biotechnics]] was acquired for $784 million.<ref>{{Cite web |title=Sanofi snaps up India's Shantha for $784M |url=http://www.fiercebiotech.com/story/sanofi-snaps-indias-shantha-784m/2009-07-27 |website=FierceBiotech|date=27 July 2009 }}</ref> In October Sanofi-Aventis announced that it would lay off about 1700 US employees (about 25% of its US workforce) because of restructuring triggered by growing generic competition and other factors, and that the company would focus its US operations on diabetes, atrial fibrillation, and oncology.<ref>{{cite news |last1=Gryta |first1=Thomas |last2=Spencer |first2=Mimosa |date=9 October 2010 |title=Sanofi Cuts Jobs, Counters Genzyme |work=The Wall Street Journal |url=https://www.wsj.com/articles/SB10001424052748704657304575540024140661094 |access-date=27 November 2019}}</ref>


In 2010, US consumer healthcare company [[Chattem|Chattem, Inc.]] was acquired for around $1.9 billion.<ref name="Chattem">{{cite news |date=21 December 2009 |title=Drug Maker Sanofi-Aventis Buys Chattem for $1.9 Billion |work=The New York Times |agency=Reuters|url=https://www.nytimes.com/2009/12/22/business/global/22drug.html |access-date=27 November 2019}}</ref> In the same year, Nepentes Pharma was acquired for $130 million and BMP Sunstone Corporation for $520.6 million.<ref>Phil Serafino for Bloomberg News. 28 October 2010 [https://www.bloomberg.com/news/2010-10-28/sanofi-aventis-to-buy-bmp-sunstone-for-520-6-million.html Sanofi-Aventis to Buy BMP Sunstone to Expand in China]</ref>
In 2010, US consumer healthcare company [[Chattem|Chattem, Inc.]] was acquired for around $1.9 billion.<ref name="Chattem">{{cite news |date=21 December 2009 |title=Drug Maker Sanofi-Aventis Buys Chattem for $1.9 Billion |work=The New York Times |agency=Reuters|url=https://www.nytimes.com/2009/12/22/business/global/22drug.html |access-date=27 November 2019}}</ref> In the same year, Nepentes Pharma was acquired for $130 million and BMP Sunstone Corporation for $520.6 million.<ref>Phil Serafino for Bloomberg News. 28 October 2010 [https://www.bloomberg.com/news/2010-10-28/sanofi-aventis-to-buy-bmp-sunstone-for-520-6-million.html Sanofi-Aventis to Buy BMP Sunstone to Expand in China]</ref>
Line 96: Line 96:
In March 2014, Sanofi joined the bidding for Merck & Co.'s over-the-counter health-products unit, the maker of [[Coppertone (sunscreen)|Coppertone]] sunblock and the antihistamine [[Pseudoephedrine/loratadine|Claritin]]; bids were expected to range between $10 billion and $12 billion.<ref>{{Cite news |last1=Baigorri |first1=Manuel |last2=Torsoli  |first2=Albertina |last3=Welch |first3=David |date=25 March 2014 |title=Sanofi Said to Join Bidders for Merck's Consumer-Health Unit |url=https://www.bloomberg.com/news/2014-03-24/sanofi-said-to-join-bidders-for-merck-s-consumer-health-business.html |work=Bloomberg News |language=en}}</ref>
In March 2014, Sanofi joined the bidding for Merck & Co.'s over-the-counter health-products unit, the maker of [[Coppertone (sunscreen)|Coppertone]] sunblock and the antihistamine [[Pseudoephedrine/loratadine|Claritin]]; bids were expected to range between $10 billion and $12 billion.<ref>{{Cite news |last1=Baigorri |first1=Manuel |last2=Torsoli  |first2=Albertina |last3=Welch |first3=David |date=25 March 2014 |title=Sanofi Said to Join Bidders for Merck's Consumer-Health Unit |url=https://www.bloomberg.com/news/2014-03-24/sanofi-said-to-join-bidders-for-merck-s-consumer-health-business.html |work=Bloomberg News |language=en}}</ref>


In October 2014, Sanofi's directors fired US-resident chief executive [[Chris Viehbacher]], blaming his alleged lack of communication with the board and poor execution of his strategy.<ref>{{Cite news |last1=Huet |first1=Natalie |last2=Mennella |first2=Noëlle |date=29 October 2014 |title=French drugmaker Sanofi sacks CEO, shares drop |url=https://www.reuters.com/article/us-sanofi-sa-management-idUSKBN0II0BH20141029 |access-date=6 July 2015 |work=Reuters }}</ref> Board chairperson Serge Weinberg took over as interim CEO until 2 April 2015 when [[Bayer|Bayer Healthcare]] board chairman [[Olivier Brandicourt]] (appointed by Sanofi on 19 February 2015<ref>{{Cite press release |title=Sanofi Appoints Olivier Brandicourt as Chief Executive Officer |date=February 19, 2015 |publisher=Sanofi |url=http://en.sanofi.com/NasdaQ_OMX/LOCAL/press_releases/sanofi___sanofi_appoints_olivi_1896027_19-02-2015!22_45_00.aspx |archive-url=https://web.archive.org/web/20150425041931/http://en.sanofi.com/NasdaQ_OMX/LOCAL/press_releases/sanofi___sanofi_appoints_olivi_1896027_19-02-2015!22_45_00.aspx |archive-date=2015-04-25}}</ref>) took over.  Before Brandicourt even started his new job, French government ministers [[Stéphane Le Foll]] and [[Ségolène Royal]] attacked the $4.5 million [[golden handshake]] he was getting from Sanofi – and his pay of about $4.7 million a year.<ref>{{cite news |last=Silverman |first=Ed |date=24 February 2015 |title=French Government Slams Sanofi Over Brandicourt Pay Package |work=[[The Wall Street Journal]] |url=https://blogs.wsj.com/pharmalot/2015/02/24/french-government-slams-sanofi-over-brandicourt-pay-package/ |access-date=6 July 2015}}</ref> Furthermore, in 2014, the business took a 66% stake in Globalpharma, a Dubai-based generics manufacturer.<ref>{{Cite web |last=Eric Palmer |date=2014-06-26 |title=Sanofi buys Dubai's Globalpharma to produce generics in the Middle East |url=http://www.fiercepharma.com/supply-chain/sanofi-buys-dubai-s-globalpharma-to-produce-generics-middle-east |access-date=2017-02-24 |publisher=Questex LLC.}}</ref>
In October 2014, Sanofi's directors fired US-resident chief executive [[Chris Viehbacher]], blaming his alleged lack of communication with the board and poor execution of his strategy.<ref>{{Cite news |last1=Huet |first1=Natalie |last2=Mennella |first2=Noëlle |date=29 October 2014 |title=French drugmaker Sanofi sacks CEO, shares drop |url=https://www.reuters.com/article/us-sanofi-sa-management-idUSKBN0II0BH20141029 |access-date=6 July 2015 |work=Reuters }}</ref> Board chairperson Serge Weinberg took over as interim CEO until 2 April 2015 when [[Bayer|Bayer Healthcare]] board chairman [[Olivier Brandicourt]] (appointed by Sanofi on 19 February 2015<ref>{{Cite press release |title=Sanofi Appoints Olivier Brandicourt as Chief Executive Officer |date=February 19, 2015 |publisher=Sanofi |url=http://en.sanofi.com/NasdaQ_OMX/LOCAL/press_releases/sanofi___sanofi_appoints_olivi_1896027_19-02-2015!22_45_00.aspx |archive-url=https://web.archive.org/web/20150425041931/http://en.sanofi.com/NasdaQ_OMX/LOCAL/press_releases/sanofi___sanofi_appoints_olivi_1896027_19-02-2015!22_45_00.aspx |archive-date=2015-04-25}}</ref>) took over.  Before Brandicourt even started his new job, French government ministers [[Stéphane Le Foll]] and [[Ségolène Royal]] attacked the $4.5 million [[golden handshake]] he was getting from Sanofi – and his pay of about $4.7 million a year.<ref>{{cite news |last=Silverman |first=Ed |date=24 February 2015 |title=French Government Slams Sanofi Over Brandicourt Pay Package |work=The Wall Street Journal |url=https://blogs.wsj.com/pharmalot/2015/02/24/french-government-slams-sanofi-over-brandicourt-pay-package/ |access-date=6 July 2015}}</ref> Furthermore, in 2014, the business took a 66% stake in Globalpharma, a Dubai-based generics manufacturer.<ref>{{Cite web |last=Eric Palmer |date=2014-06-26 |title=Sanofi buys Dubai's Globalpharma to produce generics in the Middle East |url=http://www.fiercepharma.com/supply-chain/sanofi-buys-dubai-s-globalpharma-to-produce-generics-middle-east |access-date=2017-02-24 |publisher=Questex LLC.}}</ref>


In July 2015, [[Genzyme]] announced that it would acquire the cancer drug Caprelsa ([[vandetanib]]) from [[AstraZeneca]] for up to $300 million.<ref>{{Cite web |date=2015-07-27 |title=Genzyme to Buy Caprelsa from AstraZeneca for Up to $300M - GEN News Highlights - GEN |url=http://www.genengnews.com/gen-news-highlights/genzyme-to-buy-caprelsa-from-astrazeneca-for-up-to-300m/81251554/ |website=Genengnews.com}}</ref> In the same month, the company announced a new global collaboration with [[Regeneron Pharmaceuticals]] to discover, develop, and commercialize new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,<ref>{{Cite web |date=2015-07-28 |title=Regeneron, Sanofi Launch $2B+ Immuno-Oncology Collaboration - GEN News Highlights - GEN |url=http://www.genengnews.com/gen-news-highlights/regeneron-sanofi-launch-2b-immuno-oncology-collaboration/81251558/ |website=Genengnews.com}}</ref> with $640 million upfront, $750 million for proof of concept data, and $650 million from the development of [[REGN2810]].<ref>{{Cite web |title=UPDATED: Struggling Sanofi paying $1.8B to partner with Regeneron on immuno-oncology |url=http://www.fiercebiotech.com/story/struggling-sanofi-paying-18b-partner-regeneron-immuno-oncology/2015-07-28 |website=FierceBiotech.com|date=28 July 2015 }}</ref>
In July 2015, [[Genzyme]] announced that it would acquire the cancer drug Caprelsa ([[vandetanib]]) from [[AstraZeneca]] for up to $300 million.<ref>{{Cite web |date=2015-07-27 |title=Genzyme to Buy Caprelsa from AstraZeneca for Up to $300M - GEN News Highlights - GEN |url=http://www.genengnews.com/gen-news-highlights/genzyme-to-buy-caprelsa-from-astrazeneca-for-up-to-300m/81251554/ |website=Genengnews.com}}</ref> In the same month, the company announced a new global collaboration with [[Regeneron Pharmaceuticals]] to discover, develop, and commercialize new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,<ref>{{Cite web |date=2015-07-28 |title=Regeneron, Sanofi Launch $2B+ Immuno-Oncology Collaboration - GEN News Highlights - GEN |url=http://www.genengnews.com/gen-news-highlights/regeneron-sanofi-launch-2b-immuno-oncology-collaboration/81251558/ |website=Genengnews.com}}</ref> with $640 million upfront, $750 million for proof of concept data, and $650 million from the development of [[REGN2810]].<ref>{{Cite web |title=UPDATED: Struggling Sanofi paying $1.8B to partner with Regeneron on immuno-oncology |url=http://www.fiercebiotech.com/story/struggling-sanofi-paying-18b-partner-regeneron-immuno-oncology/2015-07-28 |website=FierceBiotech.com|date=28 July 2015 }}</ref>
Retrieved from ‘https://openusaproject.com/wiki/Special:MobileDiff/17494’